Literature DB >> 24940108

The role of interventional radiology in the management of hepatocellular carcinoma.

N Molla1, N AlMenieir2, E Simoneau3, M Aljiffry4, D Valenti5, P Metrakos6, L M Boucher5, M Hassanain6.   

Abstract

BACKGROUND: Hepatocellular carcinoma (hcc) is one of the most common causes of cancer-related death worldwide. Overall, liver transplantation and resection are the only available treatments with potential for cure. Various locoregional therapies are widely used to manage patients with advanced hcc or as a bridging therapy for patients with early and intermediate disease. This article reviews and evaluates the role of interventional radiology in the management of such cases by assessing various aspects of each method, such as effect on rates of survival, recurrence, tumour response, and complications.
METHODS: A systemic search of PubMed, medline, Ovid Medline In-Process, and the Cochrane Database of Systematic Reviews retrieved all related scientific papers for review.
RESULTS: Needle core biopsy is a highly sensitive, specific, and accurate method for hcc grading. Portal-vein embolization provides adequate expansion of the future liver remnant, making more patients eligible for resection. In focal or multifocal unresectable early-stage disease, radiofrequency ablation tops all other thermoablative methods. However, microwave ablation is preferred in large tumours and in patients with Child-Pugh B disease. Cryoablation is preferred in recurrent disease and in patients who are poor candidates for anesthesia. Of the various transarterial modalities-transarterial chemoembolization (tace), drug-eluting beads, and transarterial radio-embolization (tare)-tace is the method of choice in Child-Pugh A disease, and tare is the method of choice in hcc cases with portal vein thrombosis.
CONCLUSIONS: The existing data support the importance of a multidisciplinary approach in hcc management. Large randomized controlled studies are needed to provide clear indication guidelines for each method.

Entities:  

Keywords:  Interventional radiology; ablation; drug-eluting beads; embolization; hepatocellular carcinoma; liver biopsy

Year:  2014        PMID: 24940108      PMCID: PMC4059812          DOI: 10.3747/co.21.1829

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  116 in total

1.  Irreversible electroporation for treatment of liver cancer.

Authors:  Govindarajan Narayanan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

2.  Hepatic ablation using radiofrequency electrocautery.

Authors:  J P McGahan; P D Browning; J M Brock; H Tesluk
Journal:  Invest Radiol       Date:  1990-03       Impact factor: 6.016

3.  Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction.

Authors:  Ron C Gaba; Ahsun Riaz; Robert J Lewandowski; Saad M Ibrahim; Robert K Ryu; Kent T Sato; Reed A Omary; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2010-07-03       Impact factor: 3.464

4.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

5.  Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

Authors:  S A Curley; F Izzo; L M Ellis; J Nicolas Vauthey; P Vallone
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

6.  Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto.

Authors:  I Levy; M Sherman
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

7.  Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats.

Authors:  H Egawa; A Maki; K Mori; Y Yamamoto; S Mitsuhashi; K Bannai; K Asano; K Ozawa
Journal:  J Surg Oncol       Date:  1990-06       Impact factor: 3.454

8.  Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome-a study based on 3011 patients in China.

Authors:  P Wang; Z Q Meng; Z Chen; J H Lin; B Ping; L F Wang; B H Wang; L M Liu
Journal:  Eur J Surg Oncol       Date:  2007-08-30       Impact factor: 4.424

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment.

Authors:  Emanuele Boatta; Mario Corona; Alessandro Cannavale; Fabrizio Fanelli; Carlo Cirelli; Lorenzo de Medici
Journal:  Indian J Radiol Imaging       Date:  2013-04
View more
  21 in total

1.  Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.

Authors:  Mishal Mendiratta-Lala; William Masch; Prasad R Shankar; Holly E Hartman; Matthew S Davenport; Matthew J Schipper; Chris Maurino; Kyle C Cuneo; Theodore S Lawrence; Dawn Owen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-09-10       Impact factor: 7.038

Review 2.  Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantation.

Authors:  Meera Ramanathan; Michael Shroads; Myunghan Choi; David Wood; Anil Seetharam
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 3.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

Review 4.  New treatment modalities for hepatocellular cancer.

Authors:  Kurt Mauer; Ryan O'Kelley; Nishant Podda; Siobhan Flanagan; Sameer Gadani
Journal:  Curr Gastroenterol Rep       Date:  2015-05

Review 5.  Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective.

Authors:  Jonathon Willatt; Kevin K Hannawa; Julie A Ruma; Timothy L Frankel; Dawn Owen; Pranab M Barman
Journal:  World J Hepatol       Date:  2015-02-27

Review 6.  Bridging to liver transplantation in HCC patients.

Authors:  Dagmar Kollmann; Nazia Selzner; Markus Selzner
Journal:  Langenbecks Arch Surg       Date:  2017-07-28       Impact factor: 3.445

7.  Liver targeted therapies for hepatocellular carcinoma prior to transplant: contemporary management strategies.

Authors:  Mustafa Nazzal; Sameer Gadani; Abdullah Said; Mandy Rice; Obi Okoye; Ahmad Taha; Krista L Lentine
Journal:  Glob Surg       Date:  2018-02-15

Review 8.  Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma.

Authors:  Loukia S Poulou; Evanthia Botsa; Ioanna Thanou; Panayiotis D Ziakas; Loukas Thanos
Journal:  World J Hepatol       Date:  2015-05-18

Review 9.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  The effects of percutaneous ethanol injection followed by 20-kHz ultrasound and microbubbles on rabbit hepatic tumors.

Authors:  Zhi Yong Shen; Gan Lin Xia; Ming Feng Wu; Lei Yan Ji; Yong Jun Li
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.